What Is Glucagon? Product Attributes vs. Peptide Alternatives
Abstract: Glucagon, a 29-amino acid peptide hormone, is critical for glucose homeostasis. This analysis contrasts pharmaceutical-grade glucagon products (e.g., Eli Lilly’s Glucagon Kit) with peptide alternatives (e.g., semaglutide, tirzepatide) across market trends, technical parameters, and regulatory compliance. Data shows the global peptide therapeutics market is projected at $50.6 billion by 2028 (CAGR 8.2%). Product comparisons highlight stability (lyophilized vs. liquid), purity (>98% HPLC), and cold-chain logistics (2-8°C). Brand differentiation hinges on FDA/EMA certifications, GMP factory audits, and batch-to-batch consistency. Selection criteria prioritize peptide sequence integrity, endotoxin levels, and third-party COAs. Industry trends indicate a shift toward dual-action GLP-1/GIP analogs, while glucagon remains vital for emergency hypoglycemia management.